Results for the substance baricitinib

Baricitinib is a selective Janus kinase (JAK) inhibitor used in the treatment of moderate to severe rheumatoid arthritis in adult patients who have not responded adequately to other therapies. It works by inhibiting the JAK-STAT signaling pathways, reducing inflammation and abnormal immune responses.

Baricitinib is administered orally, usually once daily, with the dose adjusted based on patient response and tolerability. It is used either as monotherapy or in combination with other disease-modifying antirheumatic drugs such as methotrexate.

Common side effects include upper respiratory tract infections, nausea, increased cholesterol levels, and elevated liver enzymes. In rare cases, severe adverse reactions such as serious infections, deep vein thrombosis, or gastrointestinal perforations may occur. Regular monitoring of hematological and metabolic parameters is essential during treatment.

Baricitinib is an innovative therapeutic option for patients with rheumatoid arthritis, contributing to symptom reduction and improved quality of life.